Literature DB >> 6083564

Evidence for an intracellular precursor for human B-cell growth factor.

C G Sahasrabuddhe, J Morgan, S Sharma, S Mehta, B Martin, D Wright, A Maizel.   

Abstract

Human B-cell growth factor has been described as a trypsin-sensitive protein of Mr 12,000-14,000. Evidence is provided herein that this relatively low molecular weight product may be released from a larger precursor molecule of Mr 60,000-80,000. The precursor protein is confined to the cytosol of freshly isolated T lymphocytes, and only the Mr 12,000-14,000 moiety is released upon lectin stimulation. The precursor protein was subjected to limited tryptic digestion, which demonstrated that the biologically active fraction of the moiety resided in a relatively low molecular weight fragment. The T lymphocyte routinely possessed an intracytoplasmic pool of the precursor protein, the amount of which cyclically varied depending upon its depletion by the secretion process of a lower molecular weight product. Analysis of the mRNA size coding for the majority of B-cell growth factor activity, determined by translation in Xenopus laevis oocytes, suggested that the B-cell growth factor-specific mRNA resided in the greater than or equal to 15S range. This value is consistent with the size of the larger precursor. Therefore, it is proposed that a precursor-product relationship exists for the processing of human B-cell growth factor, analogous to that which has been described for several other cytokines.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6083564      PMCID: PMC392261          DOI: 10.1073/pnas.81.24.7902

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  Methylmercury as a reversible denaturing agent for agarose gel electrophoresis.

Authors:  J M Bailey; N Davidson
Journal:  Anal Biochem       Date:  1976-01       Impact factor: 3.365

2.  Characterization of human B cell growth factor (BCGF) from cloned T cells or mitogen-stimulated T cells.

Authors:  K Yoshizaki; T Nakagawa; K Fukunaga; T Kaieda; S Maruyama; S Kishimoto; Y Yamamura; T Kishimoto
Journal:  J Immunol       Date:  1983-03       Impact factor: 5.422

3.  Soluble factor activation of human B lymphocytes.

Authors:  R J Ford; S R Mehta; D Franzini; R Montagna; L B Lachman; A L Maizel
Journal:  Nature       Date:  1981-11-19       Impact factor: 49.962

4.  T-cell hybridomas which produce B lymphocyte replication factors only.

Authors:  W Lernhardt; C Corbel; R Wall; F Melchers
Journal:  Nature       Date:  1982-11-25       Impact factor: 49.962

5.  Human interleukin 1: purification and properties.

Authors:  L B Lachman
Journal:  Fed Proc       Date:  1983-06

6.  Isolation and nucleotide sequence of a cDNA encoding the precursor of mouse nerve growth factor.

Authors:  J Scott; M Selby; M Urdea; M Quiroga; G I Bell; W J Rutter
Journal:  Nature       Date:  1983-04-07       Impact factor: 49.962

7.  Structure and expression of a cloned cDNA for human interleukin-2.

Authors:  T Taniguchi; H Matsui; T Fujita; C Takaoka; N Kashima; R Yoshimoto; J Hamuro
Journal:  Nature       Date:  1983 Mar 24-30       Impact factor: 49.962

8.  Nucleotide sequence of epidermal growth factor cDNA predicts a 128,000-molecular weight protein precursor.

Authors:  A Gray; T J Dull; A Ullrich
Journal:  Nature       Date:  1983 Jun 23-29       Impact factor: 49.962

9.  Evidence for pro-beta-nerve growth factor, a biosynthetic precursor to beta-nerve growth factor.

Authors:  E A Berger; E M Shooter
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

10.  Differential sensitivity of human B cell subsets to activation signals delivered by anti-mu antibody and proliferative signals delivered by a monoclonal B cell growth factor.

Authors:  A Muraguchi; J L Butler; J H Kehrl; A S Fauci
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

View more
  1 in total

1.  Modulation of the response to B-cell growth factor (BCGF) of hairy cells from a patient under IFN-alpha therapy.

Authors:  E Génot; C Mathiot; J P Kolb
Journal:  Blut       Date:  1987-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.